An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2016
At a glance
- Drugs Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 04 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Mar 2014 Planned End Date changed from 1 Sep 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 02 Nov 2013 Findings will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, according to a Gilead Sciences media release.